We are a growing best-in-class team with ophthalmologists, machine learning AI Specialists, and global business experts. Find more about how our leadership team contributes to delivering diagnostic AI in healthcare to patients that need it the most.
Kevin Taegeun Choi
Kevin Taegeun Choi is the founder and CEO of Mediwhale, a leading digital healthcare company that is the first in offering comprehensive AI diagnostic solutions. His leadership specializes in building an emerging company with strategic planning and business execution.
He founded Mediwhale on a mission to bridge the healthcare gap between medical professionals and communities through Mediwhale’s AI diagnostic solutions and empower people to know their health risks early in primary care.
He is committed to improving the accessibility and quality of healthcare for everyone in the world. He believes AI applications in healthcare that can literally improve diagnostics and patient care, detecting disease early and helping doctors make informed decisions quickly.
His vision is to set a new standard of care by offering personalized health assessment that is affordable, accessible, and safe. He received his bachelor’s degree in Industrial and Management Engineering from Pohang University of Science and Technology(POSTECH) in Korea.
Dr. Tyler Hyungtaek Rim, MD, MBA, PhD
Chief Medical Officer, Co-founder
Dr. Tyler Hyungtaek Rim, MD, MBA, Ph.D. is a fellowship-trained retina specialist, epidemiologist, and clinician scientist specializing in machine learning. He is a co-founder and chief medical officer of Mediwhale.
He was an assistant professor at Duke-NUS medical school and also a clinician scientist and machine learning researcher at Singapore Eye Research Institute (SERI) and Singapore National Eye Centre (SNEC).
Before his Artificial Intelligence and big data-related research career in Singapore, he was an assistant professor of ophthalmology at Severance Hospital, Yonsei University College of Medicine in Seoul, Korea. As a vitreoretinal surgeon, he was experienced in diagnosing and managing retinal diseases and skilled in minimal-invasive vitrectomy techniques.
His research focuses on data sciences that include biostatistics, epidemiology, big data analytics, and machine learning in ophthalmology.
Dr. Tyler H. Rim has published more than 150 scientific papers in various peer-reviewed journals including the Lancet Digital health, Ophthalmology, JAMA Ophthalmology, Stroke, Journal of Hypertension, and International Journal of Cardiology as the first or corresponding author. He received a bachelor’s degree in Chemistry from Korea Advanced Institute of Science & Technology (KAIST) and his MD and PhD from Yonsei University College of Medicine in Seoul, Korea.
Young Geunyoung Lee
Young Geunyoung Lee has served as Chief Technology Officer since Mediwhale’s inception. His interest in machine learning and programming led him to participate in a renowned Big Data Health & Science Competition in 2016 hosted by Asan Medical Center, the biggest hospital in Korea. This competition aims to provide teams with the opportunity to apply their knowledge to the analysis of big datasets in healthcare. He was the only one who signed up as a solo participant and won 2nd place.
His knowledge specializes in AI integration with medical images and software. He played a pivotal role in creating Reti-Intelligence, the foundational AI-empowered diagnostics algorithm of Mediwhale.
He co-founded Mediwahle after meeting Kevin at the Big Data Competition on a mission to improve the accessibility and quality of healthcare for everyone in the world. His goal is to establish a company that meets the needs of all healthcare players – patients, hospitals, government, and insurance companies. He received his bachelor’s degree in Nuclear Engineering from Seoul National University
Nina Shin is the COO at Mediwhale where she drives operational excellence within the company and seeks new market opportunities.
Nina brings more than a decade of leadership experience in corporate strategy development, brand management & marketing, and operations in the new digital service launch into Mediwhale. Her in-depth knowledge of the business operation and new business launch helps Mediwhale to propel forward.
Nina most recently served as a Head of Operations at Disney+ Korea, leading the launch of the Disney+ service in Korea. Previously, she led the Corporate Marketing of the Walt Disney Company Korea and served multiple roles in the Walt Disney Company Korea in theatrical marketing, digital product launch, and corporate strategy & business development. Prior to Disney, she was a global brand manager of Unilever Singapore and a management consultant at Oliver Wyman.
Nina received her MBA from Harvard Business School and has a bachelor’s degree in Business Administration from Seoul National University.
James Lim, PhD
Head of Clinical Operations
Dr. Lim has 14 years of experience in research & development in medical technology as a biomaterial scientist.
His earlier projects focus on combination device technologies, including drug-eluting metal stents, fully biodegradable polymeric stents, patent orifice occluder (PFO), injectable gel drug delivery system, and implantable vascular access device for hemodialysis application. Dr. Lim is the inventor of seven patents.
Dr. Lim is an alumnus of the Singapore Economic Development Board and a research scientist at the cardiorenal department of Mayo Clinic in the US where his invention was filed and subsequently licensed.
He was a graduate of The Agency for Science, Technology, and Research (A*STAR), a Singapore–Stanford Biodesign Program in 2012. During his time in A*STAR, Dr. Lim was the lead scientist in the implantable vascular access device project that was later spun off as Advent Access.
He also founded NephTech which specializes in providing patients with the end-stage renal disease with a non-invasive technique that detects arteriovenous fistula patency. He was in charge of mentorship and business development in Accrete Innovation, helping overseas startups enter Southeast Asia markets. Dr. Lim is trained in the implementation of ISO13485 and CE regulatory affairs by the British Standards Institution. He received his PhD degree in Material Science & Engineering from Nanyang Technological University.
Clinical Advisory Board
Professor Gregory Lip, MD
Price-Evans chair of cardiovascular medicine, University of Liverpool, UK
Professor Lip is Price-Evans chair of cardiovascular medicine, at the University of Liverpool, UK, and director of the Liverpool Centre for cardiovascular science at the University of Liverpool and Liverpool Heart & Chest Hospital. He is also a distinguished professor at Aalborg University, Denmark, an adjunct professor at Seoul National University, and Yonsei University in Korea.
Professor Lip has had a major interest in the epidemiology of atrial fibrillation, as well as the pathophysiology of thromboembolism in this arrhythmia. Furthermore, he has been researching stroke and bleeding risk factors, and improvements in clinical risk stratification.
His introduction of the Atrial fibrillation Better Care (ABC) pathway streamlines AF patient management. ABC Pathway is now recommended in guidelines: CHEST guidelines from the American College of Chest Physicians; Korean Heart Rhythm Society; ESC consensus papers; and the new 2020 ESC Guidelines. In 2014, Professor Lip was ranked by Expertscape as the world’s leading expert in the understanding and treatment of Atrial Fibrillation.
His current research interests are broad, ranging from epidemiology to pathophysiology, translational research, clinical risk assessment, trajectories of risk, patient management pathways, and applied health research. He is passionate about using ‘big data’ and epidemiological observations to generate hypotheses and to inform clinical studies that help improve the management of common cardiovascular conditions, such as atrial fibrillation, hypertension, and thrombosis.
Professor Cheng Ching-Yu, MD, PhD
Principal scientist and head, Singapore Eye Research Institute
Professor Cheng is a principal scientist and head of the Singapore Eye Research Institute. He directs the Singapore Epidemiology of Eye Diseases (SEED) Program, a large multi-disciplinary research program focusing on epidemiology, imaging, and genetics of eye diseases in Singapore. The SEED program includes one of the largest epidemiological databases (n >10,000) for eye diseases in the world.
His primary research interests are related to the epidemiology and genetics of major eye diseases. His current work involves a variety of epidemiological, clinical, and image research on glaucoma and the identification of susceptibility genes for complex ocular diseases, using both genome-wide association approaches and next-generation sequencing technology. More recently, he is also using deep learning and big data analytics based on visual images for ocular and health outcome prediction.
Professor Cheng is on the editorial board of several international journals and has received a number of prestigious awards, including the Clinician Scientist Award (CSA) from the National Medical Research Council, Singapore in 2012 and 2017, the Asia-Pacific Academy of Ophthalmology (APAO) Achievement Award, APAO Outstanding Service in Prevention of Blindness Award, and American Academy of Ophthalmology (AAO) Achievement Award.
He obtained his Doctor of Medicine degree in 1995 and specialist accreditation in Ophthalmology in 2001 from Taiwan. He received his fellowship training in Preventive Ophthalmology at Wilmer Eye Institute and completed his Master of Public Health, and PhD in Genetic Epidemiology from Johns Hopkins University.